Dyne Therapeutics (NASDAQ:DYN) Shares Down 3.7% – Time to Sell?

Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) fell 3.7% on Friday . The company traded as low as $24.36 and last traded at $24.52. 418,807 shares changed hands during trading, a decline of 43% from the average session volume of 730,030 shares. The stock had previously closed at $25.46.

Analyst Ratings Changes

A number of research analysts recently issued reports on the stock. Royal Bank of Canada began coverage on shares of Dyne Therapeutics in a research note on Tuesday, November 26th. They issued an “outperform” rating and a $45.00 price target for the company. StockNews.com downgraded shares of Dyne Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, September 16th. Chardan Capital reissued a “buy” rating and issued a $50.00 target price on shares of Dyne Therapeutics in a report on Wednesday, November 13th. Baird R W raised Dyne Therapeutics to a “strong-buy” rating in a report on Thursday, December 12th. Finally, HC Wainwright restated a “buy” rating and set a $55.00 target price on shares of Dyne Therapeutics in a research note on Wednesday, November 13th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, ten have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $50.42.

Dyne Therapeutics Stock Down 3.9 %

The firm’s fifty day moving average is $27.90 and its 200-day moving average is $34.47. The stock has a market capitalization of $2.49 billion, a PE ratio of -6.87 and a beta of 1.16.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.96) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.25). On average, analysts expect that Dyne Therapeutics, Inc. will post -3.45 EPS for the current year.

Insiders Place Their Bets

In other news, Director Jason P. Rhodes sold 782 shares of the business’s stock in a transaction that occurred on Thursday, November 14th. The shares were sold at an average price of $33.10, for a total value of $25,884.20. Following the completion of the transaction, the director now owns 15,962 shares of the company’s stock, valued at $528,342.20. The trade was a 4.67 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Oxana Beskrovnaya sold 2,334 shares of Dyne Therapeutics stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $28.12, for a total transaction of $65,632.08. Following the completion of the sale, the insider now directly owns 201,685 shares of the company’s stock, valued at $5,671,382.20. The trade was a 1.14 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 44,742 shares of company stock worth $1,443,246. 20.77% of the stock is owned by company insiders.

Institutional Investors Weigh In On Dyne Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Bank of New York Mellon Corp lifted its holdings in shares of Dyne Therapeutics by 52.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 311,504 shares of the company’s stock worth $10,993,000 after acquiring an additional 107,233 shares during the period. Rhumbline Advisers increased its stake in Dyne Therapeutics by 23.7% during the second quarter. Rhumbline Advisers now owns 121,595 shares of the company’s stock worth $4,291,000 after acquiring an additional 23,266 shares during the last quarter. TD Asset Management Inc raised its holdings in shares of Dyne Therapeutics by 103.5% in the 2nd quarter. TD Asset Management Inc now owns 152,210 shares of the company’s stock worth $5,371,000 after purchasing an additional 77,410 shares during the period. Victory Capital Management Inc. acquired a new position in shares of Dyne Therapeutics in the 2nd quarter valued at about $676,000. Finally, Arizona State Retirement System grew its holdings in shares of Dyne Therapeutics by 26.9% during the 2nd quarter. Arizona State Retirement System now owns 15,070 shares of the company’s stock worth $532,000 after purchasing an additional 3,199 shares during the period. Hedge funds and other institutional investors own 96.68% of the company’s stock.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.